Pazopanib in Von Hippel-Lindau (VHL) Syndrome

Related Clinical Trial
Propranolol and Von Hippel-Lindau Disease Retrospective Case Series of Trans-scleral Cryotherapy for Retinal Hemangioblastoma 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy Study of Brain and Spinal Cord Tumor Growth and Cyst Development in Patients With Von Hippel Lindau Disease Assessment of Residual VHL Function in Tumors – Can it Predict the Patients’ Individual Course of Disease? Phase II Study of Vandetanib in Individuals With Kidney Cancer A Phase 2 Study of PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell Carcinoma Drivers of Hypoxia-induced Angiogenesis in Tumor Development Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors MyVHL: Patient Natural History Study Metabolic Mapping to Measure Retinal Metabolism Use of Tracking Devices to Locate Abnormalities During Invasive Procedures National Eye Institute Biorepository for Retinal Diseases Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow Pazopanib in Von Hippel-Lindau (VHL) Syndrome 17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only) A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome Screening for Endolymphatic Sac Tumours (ELSTs) in Von Hippel-Lindau (vHL) Patients Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome Von Hippel-Lindau Disease Genetic Epidemiology Study Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584 TKI 258 in Von Hippel-Lindau Syndrome (VHL) Study of Sunitinib in Patients With Von Hippel-Lindau (VHL) Disease Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau Genetic Study to Identify Gene Mutations in Participants Previously Enrolled in Clinical Trial NCI-99-C-0053 Who Have Von Hippel-Lindau Syndrome or Are at Risk for Von Hippel-Lindau Syndrome PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome

Brief Title

Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome

Official Title

A Phase II Trial of Pazopanib in Von Hippel-Lindau Syndrome

Brief Summary

      This phase II trial studies the side effects and how well pazopanib hydrochloride works in
      treating patients with von Hippel-Lindau syndrome. Pazopanib hydrochloride may stop the
      growth of cancer cells by blocking some of the enzymes needed for cell growth.

Detailed Description


      I. Evaluate safety and efficacy of treatment with pazopanib hydrochloride (pazopanib) for 6
      months in patients with von Hippel-Lindau syndrome (VHL) who have a measurable VHL related


      I. Evaluate rate of growth over time in target lesions before and after pazopanib treatment.

      II. Evaluate need for surgical intervention over time in patients who receive pazopanib and
      compare to rate prior to receipt of drug.

      III. Create an annotated tissue resource from patients with VHL for use in future research
      related to cancer.


      I. Evaluate circulating factors in patients with VHL undergoing treatment with pazopanib.

      II. Evaluate relationship between VHL genotype and response to pazopanib.


      Patients receive pazopanib hydrochloride orally (PO) once daily (QD) on days 1-28. Treatment
      repeats every 4 weeks for up to 24 weeks in the absence of disease progression or
      unacceptable toxicity. Patients benefitting from treatment may continue pazopanib
      hydrochloride in the absence of disease progression.

      After completion of study treatment, patients are followed up at 30 days and then every 3
      months for up to 24 weeks.

Study Phase

Phase 2

Study Type


Primary Outcome

Overall response rate (complete response + partial response)


Von Hippel-Lindau Syndrome


Laboratory Biomarker Analysis

Study Arms / Comparison Groups

 Treatment (pazopanib hydrochloride)
Description:  Patients receive pazopanib hydrochloride PO QD on days 1-28. Treatment repeats every 4 weeks for up to 24 weeks in the absence of disease progression or unacceptable toxicity. Patients benefitting from treatment may continue pazopanib hydrochloride in the absence of disease progression.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

January 17, 2012

Completion Date

April 11, 2023

Primary Completion Date

April 11, 2023

Eligibility Criteria

        Inclusion Criteria:

          -  Subjects must provide written informed consent prior to performance of study-specific
             procedures or assessments, and must be willing to comply with treatment and follow up;
             procedures conducted as part of the subject's routine clinical management (e.g., blood
             count, imaging study) and obtained prior to signing of informed consent may be
             utilized for screening or baseline purposes provided these procedures are conducted as
             specified in the protocol

          -  Eastern Cooperative Oncology Group (ECOG) performance status of =< 2

          -  Genetically confirmed diagnosis of VHL or measurable disease consistent with the
             clinical diagnosis of VHL

          -  At least one measurable VHL related lesion, which is undergoing surveillance, and
             patient is not at immediate risk of needing intervention for this or other lesions;
             biopsy is not required given the known likely etiology and natural history in the
             setting of a positive genetic test

               -  Brain: asymptomatic hemangioblastoma, >= 0.5 cm

               -  Spine: asymptomatic hemangioblastoma, >= 0.5 cm

               -  Renal: solid mass suspicious for renal cell carcinoma (RCC) >= 1 cm or cystic
                  mass (Bosniak 3-4) >= 1 cm

               -  Pancreas: solid mass >= 1 cm and =< 3 cm suspicious for neuroendocrine tumor, or
                  neuroendocrine tumor > 3 cm but not considered operable

               -  Eye: asymptomatic peripapillary and/or macular hemangioblastoma, any size

               -  Adrenal: asymptomatic or controlled pheochromocytoma greater than 1 cm in size

          -  Patients may have received prior VHL-related systemic therapy, provided not within 14
             days or five half-lives of a drug (whichever is longer) prior to the first dose of

          -  Absolute neutrophil count (ANC) >= 1.5 X 10^9/L

          -  Hemoglobin >= 9 g/dL (5.6 mmol/L)

               -  Subjects may not have had a transfusion within 7 days of screening assessment

          -  Platelets >= 100 X 10^9/L

          -  Prothrombin time (PT) or international normalized ratio (INR) =< 1.2 X upper limit of
             normal (ULN)

               -  Subjects receiving anticoagulant therapy are eligible if their INR is stable and
                  within the recommended range for the desired level of anticoagulation or if they
                  are on low molecular weight heparin

          -  Activated partial thromboplastin time (aPTT) =< 1.2 X ULN

          -  Total bilirubin =< 1.5 X ULN

          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.0 X ULN

               -  Concomitant elevations in bilirubin and AST/ALT above 1.0 x ULN (upper limit of
                  normal) are not permitted

          -  Serum creatinine =< 2.0 mg/dL (133 umol/L) OR, if > 2.0 mg/dL: calculated creatinine
             clearance (ClCR) >= 50 mL/min

          -  Urine protein to creatinine ratio (UPC) < 1

               -  If UPC >= 1, then a 24-hour urine protein must be assessed. Subjects must have a
                  24-hour urine protein value < 1 g to be eligible

          -  A female is eligible to enter and participate in this study if she is of:
             non-childbearing potential including

               -  Any female who has had a surgical procedure rendering her incapable of becoming

               -  Subjects not using hormone replacement therapy (HRT) must have experienced total
                  cessation of menses for >= 1 year and be greater than 45 years in age, OR, in
                  questionable cases, have a follicle stimulating hormone (FSH) value > 40 mIU/mL
                  and an estradiol value < 40 pg/mL (< 140 pmol/L)

               -  Subjects using HRT must have experienced total cessation of menses for >= 1 year
                  and be greater than 45 years of age OR have had documented evidence of menopause
                  based on FSH and estradiol concentrations prior to initiation of HRT;
                  childbearing potential, including any female who has had a negative serum
                  pregnancy test within 2 weeks prior to the first dose of study treatment,
                  preferably as close to the first dose as possible, and agrees to use adequate
                  contraception GlaxoSmithKline (GSK) acceptable contraceptive methods, when used
                  consistently and in accordance with both the product label and the instructions
                  of the physician, are as follows:

                    -  Complete abstinence from sexual intercourse for 14 days before exposure to
                       investigational product, through the dosing period, and for at least 21 days
                       after the last dose of investigational product

                    -  Oral contraceptive

                    -  Injectable progestogen

                    -  Implants of levonorgestrel

                    -  Estrogenic vaginal ring

                    -  Percutaneous contraceptive patches

                    -  Intrauterine device (IUD)

                    -  Male partner sterilization

                    -  Double barrier method: condom and an occlusive cap (diaphragm or
                       cervical/vault caps) with a vaginal spermicidal agent
                       (foam/gel/film/cream/suppository); female subjects who are lactating should
                       discontinue nursing prior to the first dose of study drug and should refrain
                       from nursing throughout the treatment period and for 14 days following the
                       last dose of study drug

        Exclusion Criteria:

          -  Prior malignancy. Subjects who have had another non VHL related malignancy and have
             been disease-free for 2 years, or subjects with a history of completely resected
             non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible

          -  Clinically significant gastrointestinal abnormalities that may increase the risk for
             gastrointestinal bleeding including, but not limited to:

               -  Active peptic ulcer disease

               -  Known intraluminal metastatic lesion/s with risk of bleeding

               -  Inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease), or other
                  gastrointestinal conditions with increased risk of perforation

               -  History of abdominal fistula, gastrointestinal perforation, or intra abdominal
                  abscess within 28 days prior to beginning study treatment

          -  Clinically significant gastrointestinal abnormalities that may affect absorption of
             investigational product including, but not limited to:

               -  Malabsorption syndrome

               -  Major resection of the stomach or small bowel

          -  Presence of uncontrolled infection

          -  Corrected QT interval (QTc) > 480 msecs using Bazett's formula

          -  History of any one or more of the following cardiovascular conditions within the past
             6 months:

               -  Cardiac angioplasty or stenting

               -  Myocardial infarction

               -  Unstable angina

               -  Coronary artery bypass graft surgery

               -  Symptomatic peripheral vascular disease

               -  Class III or IV congestive heart failure, as defined by the New York Heart
                  Association (NYHA)

          -  Poorly controlled hypertension (defined as systolic blood pressure [SBP] of >= 140
             mmHg or diastolic blood pressure [DBP] of >= 90 mmHg); Note: initiation or adjustment
             of antihypertensive medication(s) is permitted prior to study entry; blood pressure
             (BP) must be re-assessed on two occasions that are separated by a minimum of 1 hour;
             on each of these occasions, the mean (of 3 readings) SBP/DBP values from each BP
             assessment must be < 140/90 mmHg in order for a subject to be eligible for the study

          -  History of cerebrovascular accident including transient ischemic attack (TIA),
             pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months;
             Note: subjects with recent DVT who have been treated with therapeutic anti-coagulating
             agents for at least 6 weeks are eligible

          -  Prior major surgery or trauma within 28 days prior to first dose of study drug and/or
             presence of any non-healing wound, fracture, or ulcer (procedures such as catheter
             placement not considered to be major)

          -  Evidence of active bleeding or bleeding diathesis

          -  Any serious and/or unstable pre-existing medical, psychiatric, or other condition that
             could interfere with subject's safety, provision of informed consent, or compliance to
             study procedures

          -  Unable or unwilling to discontinue use of prohibited medications list for at least 14
             days or five half-lives of a drug (whichever is longer) prior to the first dose of
             study drug and for the duration of the study

          -  Treatment with any of the following anti-cancer therapies:

               -  Radiation therapy, surgery or tumor embolization within 14 days prior to the
                  first dose of pazopanib OR

               -  Chemotherapy, immunotherapy, biologic therapy, investigational therapy or
                  hormonal therapy within 14 days or five half-lives of a drug (whichever is
                  longer) prior to the first dose of pazopanib

          -  Any ongoing toxicity from prior investigational therapy that is > grade 1 and/or that
             is progressing in severity, except alopecia




N/A - N/A

Accepts Healthy Volunteers



Eric Jonasch, , 

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Secondary IDs


Responsible Party


Study Sponsor

M.D. Anderson Cancer Center


 National Cancer Institute (NCI)

Study Sponsor

Eric Jonasch, Principal Investigator, M.D. Anderson Cancer Center

Verification Date

April 2022